WealthStone’s Teva Pharmaceuticals TEVA Stock Holding History

WealthStone’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-100	Closed	-$2K	–	1008
2019 Q1	$2K	Buy	+100	New	+$1.76K	0.07%	45

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WealthStone's TEVA Position: Q2 2019 in Review

WealthStone sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 100 shares — an estimated $2K sold.

WealthStone first reported a position in TEVA in Q1 2019 and held it in 1 quarter. The position peaked at $2K in Q1 2019. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

WealthStone reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
WealthStone sold 100 Teva Pharmaceuticals shares in Q2 2019, an estimated $2K.
WealthStone first reported a position in Teva Pharmaceuticals in Q1 2019 and held it in 1 quarter.
WealthStone's Teva Pharmaceuticals position peaked at $2K in Q1 2019.
452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on WealthStone's 13F filing for Q2 2019, filed 14 Aug 2019.